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E-mail address: amwu@mail.cgu.edu.tw (A.M. WuOwing to the weak reactivities of monomeric DMana1 and Galb1?3/4GlcNAcb (Ib/IIb) glycotopes with
Ralstonia solanacearum lectin (RSL), their recognition roles were previously ignored. In this study,
the interaction intensities of RSL toward four monomeric glycotopes LFuca1?, DMana1? and Ib/
IIb within two combining sites were established by both enzyme-linked lectinosorbent and inhibi-
tion assays. It was found that high density of LFuca1? complex enhanced the recognition intensities
at LFuca1? site, polyvalent DMana1?was essential for binding at the DMana1? site and polyvalent
Ib/IIb was required at LFuca1? site. The peculiar recognition systems of RSL are very different from
other well known microbial lectins.
 2012 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Ralstonia solanacearum is one of the most destructive phyto-
pathogenic bacteria on earth causing great agricultural and eco-
nomical losses [1–4]. During the past decades, the genome of this
microbe relating to the molecular basis of its virulence has been re-
vealed [5–8], including its LFuc binding lectin. RSL has a trimetric
structure (MW 30 kDa) composed of 90 amino acids (10 kDa) sub-
units containing two LFuc binding domains per subunit [7–8]. This
lectin showed stronger afﬁnity for papain-treated human erythro-
cytes regardless of their O, A, B and AB types and it also interacted
with human saliva of H and Lea,b phenotypes [7]. Its sugar-binding
preference was studied by thermodynamical and crystallographic
approaches with various monomeric ligands [7–8], and also by
both enzyme-linked lectinosorbent (ELLSA) and inhibition assays
[9]. It has been characterized as LFuc > DMan. Due to its poor reac-
tivities toward monomeric DMan and Galb1?3/4GlcNAcb (Ib/IIb),
their recognition roles were not fully identiﬁed. The theme of this
study is to examine comprehensively the relative intensities of rec-
ognition factors of RSL and their mechanisms by ELLSA and inhibi-
tion of recognition processes through RSL binding to three different
glycans: (i) polyvalent Fuca1? glycan (asialo PSM, asialo porcineon behalf of the Federation of Euro
).salivary glycoprotein), (ii) poly DMana1? containing mannan
and (iii) Pneumococcus type 14 capsular polysaccharide of IIb
repeating units. From the results, we established an advanced con-
cept of different reactivities and mechanisms of four glycotope
(LFuca?, DMana?, Galb1–3/4GlcNAcb) sharing two different com-
bining sites (LFuca1?2Galb3?3/4GlcNAc and DMana1) of RSL in
the ﬁeld of lectin recognition factors and combining sites, i.e. these
two different sites can adopt four different glycotopes of LFuca1?
and DMana1? and Ib/IIb. Furthermore, high density of LFuca1?
complex enhanced the recognition intensities at LFuca1? domi-
nant site, polyvalent DMana1? was essential for binding at the
DMana1? site and polyvalent Ib/IIb were required at LFuca1? site.
They should be involved in the mammalian and microbial glycan
recognition [5–8]. It is obvious that the recognition mechanism
for RSL–mammalian glycan interactions is very different from
those of Pseudomonas aeruginosa-II lectin (PA-IIL) [10] and Agaricus
bisporus agglutinin (ABA) [11]. The model of RSL, having two differ-
ent combining sites for adopting both LFuca1?2Galb3?3/4GlcNAc
and DMana1? glycotopes, differs from that of PA-IIL where there
is only one LFuc site for accommodating both LFuca1? and DMa-
na1? glycotopes [10]. The results of this work and our current
studies have advanced the classical concept of the lectin recogni-
tion (combining) sites [10–12]. It is expected that the combining
sites of microbial lectins should be more complicated than those
of other lectins and antibodies for adapting their sophisticated bio-
logical functions.pean Biochemical Societies.
Fig. 2. Polyvalent Mana1? glycoform in Mannan-A generalized structure of
mannan isolated from the yeast Saccharomyces cerevisiae, which consists of complex
a1?6 linked DMan backbone with a1?2/3 linked DMan side chains and Man-
phosphate (PO4 ) sub-branch in its side chain [22–23]. High Mana1? density is
required for RSL–glycan recognition (#5 in Table 1).
Fig. 3. Structural unit of Polyvalent Galb1?4GlcNAcb glycoforms as in repeating
unit of the Pneumococcus type 14 capsular polysaccharide [21,24]. The shaded
polyvalent area (IIb, Galb1?4GlcNAcb) is the essential glycotope for RSL binding to
this compound (#6 in Table 1).
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2.1. The Ralstonia solanacearum lectin (RSL)
RSL was puriﬁed from the bacterial extracts (R. solanacearum
ATCC 11696) as previously described [7–9]. RSL used for studying
was biotinylated by the method established by Duk et al. [13].
2.2. Glycoproteins and polysaccharides
Porcine salivary glycoprotein with human blood A + H activities
(Structure 1a in Fig. 1) was puriﬁed according to the procedure of
Tettamanti and Pigman and its modiﬁcations [14–15].
ABH and Lewis active blood group active glycoproteins (Cyst
Mcdon and Tighe; Structure 1b in Fig. 1) were prepared from hu-
man ovarian cyst ﬂuid [16–19]. Human a1-acid gps and fetuin,
which contain multi-antennary Galb1?4GlcNAc (II) containing
N-glycans [20–21], were purchased from Sigma–Aldrich (St Louis,
MO, USA). Desialylation was performed by mild acid hydrolysis
in 0.01 N HCl at 80 C for 90 min and followed by dialysis against
distilled H2O for 2 days to remove small fragments [14–15].
Yeast mannan (Structure in Fig. 2), isolated from Saccharomyces
cerevisiae [22–23] consisting of DMan a1?6 backbone and a1?2/3
side chains was purchased from Sigma–Aldrich (St Louis, MO, USA).
Pneumococcus type 14 capsular polysaccharide (Structure in
Fig. 3) was prepared as described previously [21,24].Fig. 1. Two Chemical structures of polyvalent LFuca1? glycoforms in human blood group
and (b) human ovarian cyst glycoproteins (cyst gp) [16–19]. Heavy shaded area: pote
glycotopes, in which Ib/IIb are exposed after removal of terminal GalNAca1?, LFuca1?2.3. Sugars used for inhibition studies
Monosaccharides and oligosaccharides were purchased from
Sigma–Aldrich (St Louis, MO, USA) and Dextra (Berkshire, UK).A and H active O-glycans. (a) asialo porcine salivary glycoproteins (asialo PSM) [14]
nt glycotopes (LFuca?2), light shaded area: Ga1b1?3/4GlcNAcb (Ib/IIb) are weak
glycotopes as in the cyst P-1 glycoprotein and Cyst Tighe Phenol P-1 [18].
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The assays were performed according to the procedures de-
scribed previously [13]. The volume of each reagent applied to
the plate was 50 ll/well, and all incubations, except for coating,
were performed at room temperature. The reagents, if not indi-
cated otherwise, were diluted with Tris-buffered saline (TBS,
0.05 M Tris, 0.15 M NaCl, pH 7.35) in 0.05% Tween 20 (TBS-T buf-
fer). The TBS-T buffer was used for washing the plate between
incubations. For inhibition studies, the serially diluted inhibitor
samples were mixed with an equal volume of lectin solution con-
taining a ﬁxed amount of RSL. The control lectin sample was di-
luted twofold with TBS-T. After 30 min at room temperature, the
samples were tested by the binding assay, as described by Duk
et al. [13]. The inhibitory activity was estimated from the inhibi-
tion curve and is expressed as the amounts of inhibitors (nano-
gram/well) giving 50% inhibition of the control lectin binding.
3. Results
3.1. Interactions of RSL with diverse glycans
The avidities of RSL to various glycoproteins and polysaccha-
rides analyzed by ELLSA are summarized in Table 1. Among the
polyvalent glycotopes tested, RSL reacted best with two polyvalent
GalNAca1?3[LFuca1?2] Gal glycoforms (blood group A active
glycoproteins, #1 and #2) and less than 0.8 ng was required for
1.5 units of absorbance at 405 nm. It also bound strongly to other
polyvalent LFuca1?2 glycoproteins (#3 and #4), a polyvalent
Mana1 polysaccharide (yeast mannan, #5), and a polyvalent
Galb1?4GalNAc glycoform (poly-IIb, Pneumococcus type 14 capsu-
lar polysaccharide, #6). But, it reacted weak and poorly with low
density DMana1? oligomer in N-glycans (#7–#10), suggesting
that: (i) LFuca1? containing glycans; (ii) polyvalent IIb glycotopes
and (iii) high density DMana1? glycotopes, such as yeast mannan,
play major roles in RSL recognition.
3.2. Inhibition of RSL–glycan binding
In order to elucidate the puzzle of the RSL recognition sites and
systems, diverse LFuc, DMan and Ib/IIb related glycans were used to
inhibit the interactions of RSL with the following three RSL active
glycans (#1, #5 and #6 in Table 1): (i) a polyvalent LFuc-containing
glycan (asialo PSM, Structure 1a in Fig. 1), (ii) a high density poly
DMana1? containing mannan (Structure in Fig. 2) and (iii) a polyTable 1
Recognition intensities of RSL to human blood group ABH active O-linked glycoproteins, si
No. (#) Glycoprotein lectin determinantsb (Blood group speciﬁcity)
1 Asialo PSM (Ah, H in O-glycan)
2 Cyst Mcdon (Ah in O-glycan)
3 Cyst JS phenol insoluble (H, LFuca1? in O-glycan)
4 Cyst Tighe phenol insoluble (H, LFuca1? in O-glycan)
5 Mannan (high density of DMana1? polysaccharide)
6 Pneumococcus type 14 capsular polysaccharide (poly IIb)
7 Asialo human a1-acid glycoprotein (IIb in N-glycan)
8 Human a1-acid glycoprotein (sialyl IIb in N-glycan)
9 Asialo fetuin (IIb in N-glycan)
10 Fetuin (sialyl IIb in N-glycan)
a 10 ng of biotinylated RSL was added to various glycoproteins/polysaccharides, rangi
b The symbols in parentheses indicate the human blood group activity and/
NAca1?3[LFuca1?2]Gal); Ib/IIb (Galb1?3/4GlcNAcb).
c The results were interpreted according to the spectrophotometric absorbance (
4+(2.5 > A405P 2.0), 3+(2.0 > A405P 1.5), 2+(1.5 > A405P 1.0), + (1.0 > A405P 0.5), ± (0.5
d Adopted from [9].IIb complex from Pneumococcus type 14 capsular polysaccharide
(Structure in Fig. 3). The amounts (nanograms) of these com-
pounds required for 50% mass inhibition of binding are listed in Ta-
bles 2 and 3.
3.2.1. Inhibition of RSL–asialo PSM interaction
The inhibition proﬁle of RSL–polyvalent LFuca1? glycan (asialo
PSM) binding by various saccharides (#7, #11–#13) and their poly-
glycoforms (#1–#6, #8–#10) are shown in Table 2a. Among the
monomeric saccharides and their polyform tested, the LFuca1?
containing glycoprotein (#1, Cyst Mcdon) was the best inhibitor,
being up to 4.0  103 and 1.7  102 times more active than DMan
and LFuc, respectively. Other LFuca1? containing O-glycans (#2,
#3 and #5) also strongly inhibited this interaction. When the poly-
valent weak IIb complexes were tested, Beach P-1 (#6) was the
best—about 455 and 20 times more active than DMan and LFuc
respectively (#7 and #13). Other polyvalent IIb glycoforms (#8–
#10) were about 12 to 19 times more potent than DMan. The re-
sults that mannan was inactive indicate the recognition site for
DMana1? related glycotopes is not at LFuc site, which was further
conﬁrmed in Section 3.2.2.
3.2.2. Inhibition of RSL–mannan interaction
When the LFuc-, DMan- and Ib/IIb-related mono/oligosaccha-
rides and glycans were used to inhibit RSL interaction with high
density poly DMana1? containing glycan (mannan, Structure in
Fig. 2), the amounts (nanograms) of these saccharides and glyco-
proteins required for 50% mass inhibition of binding were listed
in Table 2b. In contrast to the data shown in Section 3.2.1, the high
density of poly DMana1? (#1) was the best, being 106 times more
active than DMan and LFuc (# 6 and #8), while all the polyvalent
LFuca1? related glycans (#11–#13) were inactive. Except for
Pneumococcus type 14 capsular polysaccharide (#2), all other poly
IIb-related glycoforms (#3, #5 and #10) were also weak reagents.
Mapping the interaction proﬁles, it is implied that the combining
site of this system (DMana1?) should be different from that of
LFuca1? as described in Section 3.2.1.
3.2.3. Inhibition of RSL–poly IIb glycotopes interaction
Polyvalent IIb glycan from Pneumococcus type 14 capsular poly-
saccharide was one of active glycans (#6 in Table 1) even the
monomeric Ib/IIb were inactive [9]. In order to elucidate this result,
the recognition mechanism of RSL was further examined by inhibi-
tion of RSL–IIb glycan interaction by same batch of glycans. Among
these glycans tested, as shown in Table 3, two polyvalent IIbalo-/asialo N-linked glycoproteins and microbial polysaccharides analyzed by ELLSAa.
1.5 (A405) unit (ng) Maximum A405 absorbance
Absorbance reading Binding intensityc
0.5d 3.5 5+
0.8d 3.8 5+
3.0d 3.8 5+
3.8d 2.5 5+
4.5d 3.2 5+
285.0d 2.1d 4+d
636.0 1.4 2+
–d 0.9 +
–d 0.0 
–d 0.2 ±
ng from 0.01 ng to 5 lg/well.
or lectin determinants. Expressed in bold are: H (LFuca1?2Gal); Ah (Gal-
O.D.) value at 405 nm (i.e. A405 after 2 h incubation as follows: 5+(A405P 2.5,
> A405P 0.2), and  (A405 < 0.2).
Table 2
Amounts of various glycans and monosaccharides giving 50% inhibition of RSL (5 ng/50 ll) binding to a polyvalent LFuca1? containing glycan (asialo PSM, 10 ng/50 ll) and to
high density of a poly DMana1? containing glycan (mannan, 20 ng/50 ll)a.
No.(#) Inhibitorb Quantity giving 50% inhibition (ng) Mass Relative potencyc
DMan as 1.0 LFuc as 1.0
a. Inhibition of monosaccharides and glycans to asialo PSM—RSL recognition at LFuca1? site
1 Cyst Mcdon (Ah in O-glycan) 0.85d 4.0  103 171.8
2 Cyst Tighe phenol insoluble (H, LFuca1? in O-glycan) 1.4d 2.5  103 104.3
3 Cyst JS phenol insoluble (H, LFuca1? in O-glycan) 1.8d 2.0  103 81.1
4 Aisalo PSM (Ah, H in O-glycan) 3.9d 887.1 37.4
5 Beach phenol insoluble (Bh in O-glycan) 7.0d 494.3 20.9
6 Beach P-1 (Ib/IIb in O-glycan) 7.6 455.2 19.2
7 LFuc 146.0d 23.7 1.0
8 Asialo human a1-acid glycoprotein (IIb in N-glycan) 185.0 18.7 0.8
9 Cyst Mcdon P-1(Ib/IIb in O-glycan) 190.0 18.2 0.8
10 Pneumococcus type 14 capsular polysaccharide (poly IIb) 277.0d 12.5 0.5
11 LGal 432.5d 8.0 0.3
12 DAra 2266.5d 1.5 0.1
13 DMan 3459.8d 1.0 <0.1
14 Mannan (high density of DMana1?polysaccharide) >2.8  102 (5.9% inhibition) – –
b. Inhibition of monosaccharides and glycans to mannan—RSL recognition at DMana1? site
1 Mannan (high density of DMana1?polysaccharide) 0.1 1.2  106 1.3  106
2 Pneumococcus type 14 capsular polysaccharide (poly IIb) 24.0 5.0  103 5.4  103
3 Beach P-1 (Ib/IIb in O-glycan) 2.2  103 54.5 59.1
4 Cyst Mcdon (Ah in O-glycan) 2.5  103 48.2 52.0
5 Asialo human a1-acid glycoprotein (IIb in N-glycan) 5.2  103 22.9 25.0
6 DMan 1.2  105 1.0 1.1
7 LGal 1.2  105 1.0 1.1
8 LFuc 1.3  105 0.9 1.0
9 DAra 2.3  105 0.5 0.6
10 Cyst Mcdon P-1(Ib/IIb in O-glycan) >2.8  103 (27.9% inhibition) – –
11 Cyst JS phenol insoluble (H, LFuca1? in O-glycan) >2.8  103 (0.0% inhibition) – –
12 Cyst Tighe phenol insoluble (H, LFuca1? in O-glycan) >2.8  103 (20.5% inhibition) – –
13 Asialo PSM (Ah, H in O-glycan) >1.1  104 (4.7% inhibition) – –
a The inhibitory activity is expressed as the amount of inhibitor (nanogram) giving 50% inhibition. Total volume is 50 ll.
b The symbols in parentheses indicate the human blood group activity and/or lectin determinants. Expressed in bold are: H (LFuca1?2Gal); Bh (Gala1?3[LFuca1?2]Gal);
Ah (GalNAca1?3[LFuca1?2]Gal); Ib/IIb (Galb1?3/4GlcNAcb).
c Relative potency of glycoproteins compared to DMan and LFuc which were taken as 1.0.
d Adopted from [9].
Table 3
Amounts of various polyvalent glycotopes and saccharides giving 50% inhibition of RSL (5 ng/50 ll) binding to Galb1?4GlcNAcb repeating glycan (Pneumococcus type 14 capsular
polysaccharide, 500 ng/50 ll)a.
No (#) Inhibitorb Quantity giving 50% inhibition (ng) Mass relative potencyc
DMan as 1.0 LFuc as 1.0
Polyvalent glycotopes (glycoproteins/polysaccharides)
1 Cyst JS phenol insoluble (H, LFuca1? in O-glycan) 1.2 1.0  104 133.3
2 Cyst Tighe phenol insoluble (H, LFuca1? in O-glycan) 1.7 7.1  103 94.1
3 Cyst Mcdon (Ah in O-glycan) 4.3 2.8  103 37.2
4 Asialo PSM (Ah, H in O-glycan) 13.0 923.1 12.3
5 Beach P-1 (Ib/IIb in O-glycan) 26.0 461.5 6.2
6 Cyst Tighe phenol P-1 (Ib/IIb in O-glycan) 180.0 66.7 0.9
7 Asialo human a1-acid glycoprotein (IIb in N-glycan) 180.0 66.7 0.9
8 Pneumococcus type 14 capsular polysaccharide (repeating unit of IIb) 400.0 30.0 0.4
9 Human a1-acid glycoprotein (sialyl IIb in N-glycan) 2.9  103 4.1 0.1
10 Mannan (high density of DMana1?polysaccharide) 1.3  104 0.9 1.0  102
Monomeric glycotopes/disaccharides
11 LFuc 160.0 75.0 1.0
12 LGal 330.0 36.4 0.5
13 DAra 1.0  104 1.2 2.0  102
14 DMan 1.2  104 1.0 1.0  102
15 DGal 1.7  106 1.0  102 1.0  104
16 Galb1–4Glc (L) >2.7  105 (24.1% inhibition) – –
17 GlcNAc >3.8  106 (27.5% inhibition) – –
a The inhibitory activity is expressed as the amount of inhibitor (nanogram) giving 50% inhibition. Total volume is 50 ll.
b The symbols in parentheses indicate the human blood group activity and/or lectin determinants. Expressed in bold are: H (LFuca1?2Gal); Bh (Gala1?3[LFuca1?2]Gal);
Ah (GalNAca1?3[LFuca1?2]Gal); Ib/IIb (Galb1?3/4GlcNAcb).
c Relative potency of glycoproteins compared to DMan and LFuc which were taken as 1.0.
A.M. Wu et al. / FEBS Letters 586 (2012) 1294–1299 1297glycotopes tested were active inhibitors (#7 and #8). Furthermore,
LFuca1? and Ib/IIb related glycans (#1–#6) were active inhibitors.
They can be up to 1.0  104 and 133 times stronger than mono-meric DMan (#14) and monomeric LFuc (#11) respectively, while
effect of mannan (#10) was negligible, suggesting that the recogni-
1298 A.M. Wu et al. / FEBS Letters 586 (2012) 1294–1299tion sites for Ib/IIb binding are mainly located at LFuc site. The
major recognition intensities of RSL toward Ib/IIb glycans may be
driven from subsite of LFuca1? site (LFuca1?2Galb1?3/
4GlcNAc).
4. Discussion
4.1. Two Recognition (Combining) sites of RSL and polyvalent effect on
relative glycotope intensities
In this study, the natural polyvalent glycoforms used are not al-
ways homogenous, but they are still the most ideal reagents avail-
able for understanding the natural recognition processes (Tables 2
and 3). From interaction proﬁle of RSL with various glycans and
polysaccharides (Table 1), the polyvalent forms of weak glycotopes
(#5, DMana1? and #6, IIb) can become potent recognition factors.
In order to clarify these perplexities, the diverse polyvalent forms
of LFuc, DMan and Ib/IIb glycotopes (glycans) were chosen for
studying inhibitory proﬁles of three different RSL-glycan interac-
tions (#1, #5 and #6 in Table 1). The results of this assay are clearly
illustrated in Tables 2&3. When the various glycans tested, LFu-
ca1? related glycans (#1–#5 in Table 2a) inhibited only RSL–poly
LFuca1? glycoform (asialo PSM) interaction, but they did not block
RSL–mannan interaction (#11–#13 in Table 2b). Mannan (#1 in
Table 2b) was a potent inhibitor for RSL–mannan recognition, but
it was a poor ligand for RSL–poly LFuca1? glycan interaction
(#14 in Table 2a). Based on these results, it is proposed that two
different recognition sites (LFuca1? and DMana1?) must coexist
in the carbohydrate recognition systems of RSL.
Another proﬁles of diverse glycans (LFuca1?, Ib/IIb and man-
nan) to inhibit RSL–polyvalent IIb glycotopes (Pneumococcus type
14 capsular polysaccharide) binding were also used to explore
the effect of Ib/IIb polyvalency on RSL recognition. As the data
shown in Table 3, most LFuca1? related glycans tested (#1–#4)
displayed very potent inhibitors for RSL–polyvalent IIb glycan
interaction. It was ranged from 1.3  102 to 12.3 and between
1.0  104 and 9.2  102 times higher potency than LFuc and DMan,
respectively, while the Pneumococcus type 14 capsular polysaccha-
ride (poly-IIb glycoform) itself was a weak inhibitor and polyvalent
DMana1? glycan (mannan) was 30 times weaker (#10 in Table 3).
From the inhibitory proﬁle of glycans shown in Table 3, we pro-
posed that their major recognition site must be located at the sub-
site sequences (Galb1?3/4GlcNAc) of LFuca1? combining site.
While Galb1?3/4GlcNAc (Ib/IIb) are independent (without LFu-
ca1?), poly forms of the glycoforms such as Pneumococcus type
14 capsular polysaccharide and P-1 cyst glycoproteins can also
act as RSL recognition factors (#5–#8 in Table 3).
From the data provided from Table 1 (#5) and Table 2b (#1), it
is found a special conformation of multiple DMana1? linkages as
in mannan can also act as one of the active RSL recognition factors.
4.2. Conclusions of our studies
Summarizing the results of all our studies, it is concluded that:
(i) different relative intensities of four mammalian structural units,
LFuca1?, DMana1? and Ib/IIb glycotopes construct notable four
different recognition systems for RSL–glycan interactions; in which
(ii) two different combining sites (LFuca1? and DMana1?) should
be co-existing in RSL recognition systems (#1–#14 vs. #15–#27 in
Table 2); (iii) the size of LFuca1? combining site at RSL should be
as large as trisaccharide and most complementary to LFuca1?2-
Galb1?3/4GlcNAc sequences; (iv) the LFuca1? combining site of
RSL consists of cavity type as major site for accommodating LFu-
ca1? and a groove type as subsite for adopting Galb1?3/4GlcNAc
at the reducing end; (v) the optimal high density and speciﬁc stericconformation of LFuca1? complexes enhance RSL binding; (vi)
polyvalency of DMana1? is required for the recognition processes
at the DMana1? combining site; (vii) as an independent recogni-
tion factor, polyvalency of Ib/IIb is essential for LFuca1? combining
site; (viii) the order of potency of glycotope units is LFuc > DMan,
while the polyvalency required for DMana1? and Ib/IIb is greater
than that of LFuca1?; (ix) due to the complexity of mannan, struc-
tural aspect of DMana1? combining site has to be further investi-
gated. This peculiar concept of four recognition systems at two
different combining sites provides one of advanced comprehensive
knowledges about the combining sites of RSL, which creates an ad-
vanced understanding of the virulence factors of R. solanacearum
lectin at the super (polyvalent glycotopes) and sub-molecular
levels.
4.3. Recognition (combining) sites of lectins vs. antibodies
Previous studies on the recognition factors of RSL indicated that
LFuc was the most active monosaccharide. When it is linked to
non-reducing end of Galb1?3/4GlcNAcb (Ib/IIb) disaccharide se-
quences, the reactivity of RSL toward the resulting trisaccharides
(LFuca1?2Galb1?3/4 GlcNAc) was signiﬁcantly increased [9]. As
a result, it is proposed that the LFuca1? recognition site should
consist of a combination of a cavity shape as major site for the
accommodating LFuca1? monosaccharide and a groove shape as
subsite for adopting Ib/IIb glycotopes. This subsite must function
as enhancement role.
In previous concept, the shapes of combining sites of antibodies
have been classiﬁed into two groups—the cavity and the groove
shapes [12]. After our studies for over 30 years, we suggest that
the combining sites of most lectins appear to be more complicated
than originally expected, especially the microbial lectins. Recently,
we found that different intensities of four mammalian structural
units construct three recognition systems at the same combining
site for Agaricus bisporus agglutinin–glycan interactions [11] in
which the inhibitory proﬁles are similar. We also demonstrated
that ‘‘Duality of the carbohydrate-recognition system of Pseudomo-
nas aeruginosa-II lectin (PA-IIL)’’ sharing the same conﬁgurations of
epimeric-OH at carbon-2, and -4 of LFuc for both LFuc-containing
glycans and mannan recognition [10]. Now, at least three types
of combining sites–cavity, groove and hybrid types (cavity as ma-
jor site and groove as subsite)–are co-existing in plant lectins.
From the results of our recent studies, it is quite certain that the
classical structural concept of the combining sites of lectins pro-
posed by Kabat has been upgraded and expanded [10–11].
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